Abstract
Objectives
The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) has updated its 2011 guidelines on the prevention of post-contrast acute kidney injury (PC-AKI). The results of the literature review and the recommendations based on it, which were used to prepare the new guidelines, are presented in two papers.
Areas covered in part 2
Topics reviewed include stratification of PC-AKI risk, the need to withdraw nephrotoxic medication, PC-AKI prophylaxis with hydration or drugs, the use of metformin in diabetic patients receiving contrast medium and the need to alter dialysis schedules in patients receiving contrast medium.
Key points
• In CKD, hydration reduces the PC-AKI risk
• Intravenous normal saline and intravenous sodium bicarbonate provide equally effective prophylaxis
• No drugs have been consistently shown to reduce the risk of PC-AKI
• Stop metformin from the time of contrast medium administration if eGFR < 30 ml/min/1.73 m 2
• Dialysis schedules need not change when intravascular contrast medium is given
Avoid common mistakes on your manuscript.
Introduction
The Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) produced their most recent guidelines on what was then termed contrast-induced nephropathy (CIN) in 2011 [1]. Guidelines on the use of contrast media (CM) in patients on dialysis and on the use of CM in diabetic patients using metformin were published in 2002 and 2014 [2, 3]. This review provides recommendations for updating the CMSC guidelines which were obtained using a structured literature review based on clinical questions and Patient–Intervention–Comparator–Outcome (PICO) formatting. Since the literature related to the topics considered is so large, the results of the review have been split into two papers. The review only considers post-contrast kidney injury (PC-AKI) after iodine-based CM because acute kidney injury is not associated with gadolinium-based contrast agents in doses approved for clinical magnetic resonance imaging.
In this second paper on PC-AKI, the following topics related to patient management are considered:
-
1.
The role of questionnaires and risk scores to identify at-risk patients with reduced renal function
-
2.
The need to stop nephrotoxic medication before giving CM
-
3.
The optimal hydration protocols for protecting against PC-AKI
-
4.
The possible role of prophylactic drug treatment in preventing PC-AKI
-
5.
The need to adapt metformin administration when giving CM
-
6.
The need to alter schedules for dialysis in the period before and after CM administration
Recommendations are made for items 1–6. The recommendations have been incorporated into version 10 of the ESUR CMSC guidelines, at the end of this paper (Table 4).
Materials and methods
The recommendations were prepared using the Appraisal of Guidelines for Research and Evaluation (AGREE) II document [4]. A guideline Writing Group (WG) prepared ten clinical questions in PICO format [5]. Systematic search strings were developed with a professional librarian for four different biomedical literature databases (PubMed, Web of Science, Embase and the Cochrane Library). The titles and abstracts were screened for relevance and selected on predefined inclusion and exclusion criteria. Emphasis was put on comparative studies with strong scientific evidence, such as meta-analyses and systematic reviews, and prospective randomised controlled trials (RCTs). The six systematic searches in this manuscript yielded 3402 references of which 445 were selected on the basis of title and abstract. After review of the full text of these 445 publications, 145 were selected for inclusion in this paper. The quality of the evidence from the selected articles was evaluated according to the Oxford Centre for Evidence Based Medicine levels of evidence: grade A, established scientific evidence; grade B, scientific presumption; grade C, low level of evidence [6]. When there was no scientific evidence, recommendations were based on WG consensus and were graded as expert opinion (grade D).
The full description of the materials and methods appears in part 1.
The term intra-arterial injection with first pass renal exposure indicates that contrast medium reaches the kidneys in a relatively undiluted form, e.g. injection into the left heart, thoracic and suprarenal abdominal aorta or the renal arteries. The term intra-arterial injection with second pass renal exposure indicates that contrast medium reaches the renal arteries after dilution either in the pulmonary or peripheral circulation, e.g. injection into the right heart, pulmonary artery, carotid, subclavian, coronary, mesenteric or infrarenal arteries.
Results
Question 5: Should questionnaires or scoring systems be used for risk stratification by clinicians when they request a contrast-enhanced imaging study?
Patient questionnaires
Questionnaires, such as that proposed by Choyke [7], use information about a history of renal disease or renal surgery, heart failure, diabetes, proteinuria, hypertension and gout to stratify patients for their PC-AKI risk so that sCr measurements need only be done selectively. This may work well and can save resources [8]. Observational studies have shown that these questionnaires can identify patients with eGFR < 45 ml/min/1.73 m2 with adequate sensitivity, especially if they are aged less than 70 [9,10,11]. Since eGFR measurement can detect more patients with renal dysfunction than questionnaires [12], with easier patient logistics and similar cost-effectiveness [13, 14], many hospitals have adopted a policy of sCr measurements in all patients scheduled for intravenous (IV) CM and no longer use questionnaires for risk stratification or selection for eGFR measurement (Table 1).
Risk prediction models
No risk models have been produced yet for IV or IA CM administration with second pass renal exposure. For patients having coronary angiography (CA) or percutaneous coronary intervention (PCI), many different risk scores have been proposed to stratify the patient’s PC-AKI risk, and most include pre-procedural and procedural data. A model with only pre-procedural data [15] would be more practical for selecting suitable preventive measures. Risk scores should be verified in relation to improvements in clinical outcome. In clinical practice, a prediction rule would require a high discriminatory value, i.e. a C-statistic greater than 0.80 [16].
The best-known risk model is the eight-variable Mehran score [17], which has been studied in more than 15,000 patients and has been externally validated in multiple studies, but with variable C-statistic values of 0.57–0.85 [16, 18,19,20]. The Mehran score correlates relatively well with clinical outcomes [21]. Newer risk scores with good discriminatory value, available in user-friendly calculators or smartphone applications, still need external validation [22]. A recent systematic review of 16 risk models concluded that they had only modest predictive value [23] and a review and meta-analysis of 74 risk models noted their heterogeneity and concluded that further research was needed to evaluate the effect of such models on clinical care [24] (Table 1).
Question 6: Should nephrotoxic medication be withheld to reduce the risk of PC-AKI?
Optimal nephrologic care involves minimizing the use of nephrotoxic drugs where clinically possible [25]. Many frequently prescribed medications, such as nonselective NSAIDs, selective Cox-2 inhibitors, several classes of antimicrobial agents and chemotherapeutic agents have nephrotoxic potential and can induce AKI [26].
There is little good quality data about the relationship between these drugs and PC-AKI [27]. A retrospective cohort study showed that concurrent use of four or more nephrotoxic agents was significantly predictive for PC-AKI in patients given IV CM [28]. A meta-analysis of PC-AKI incidence following CM-enhanced CT found that concurrent administration of NSAIDs was an independent risk factor for PC-AKI [29].
The effect of withholding angiotensin converting enzyme inhibitors (ACEI) and angiotensin-2 receptor blockers (ARB) in chronic users has been extensively evaluated. Multiple RCTs [30, 31] and observational studies gave conflicting results and are limited by small sample sizes and significant heterogeneity [32,33,34]. However, meta-analyses of RCTs found no lower risk [34]. Withholding ACEI/ARB may be associated with a slightly lower risk of PC-AKI but the evidence is not sufficiently strong to recommend this (Table 1).
Question 7: What are the most cost- and time-effective protocols for oral and intravenous hydration to reduce the risk of PC-AKI?
Hydration as a preventive strategy for PC-AKI
Evidence for prevention of PC-AKI with IV saline hydration (volume expansion) comes from RCTs in patients who received intra-arterial (IA) CM during percutaneous intervention [35,36,37], and in patients who received bicarbonate hydration before IV enhanced emergency CTPA [38]. One RCT evaluated the evidence for IA CM administration during CA [39]. These studies found that, for both IA and IV CM administration, the incidence of PC-AKI was significantly lower in patients who received IV hydration compared to placebo, and that hydration prevented emergency dialysis [36]. Significant differences for mortality or other adverse events were not found. There were few patients with severe renal impairment (eGFR < 30 ml/min/1.73 m2) in almost all studies. The recent AMACING trial showed that for patients with eGFR > 30 ml/min/1.73 m2 receiving IV CM there was no difference between no hydration and hydration in preventing PC-AKI [40].
Oral hydration versus intravenous saline hydration
Oral intake of clear fluids by patients as an alternative to IV saline to prevent PC-AKI is difficult to monitor or control. Nine studies evaluated oral hydration, but were limited by small patient numbers and by the absence of patients with severe renal impairment [39, 41,42,43,44,45,46,47,48]. Three meta-analyses concluded that there is no evidence that oral hydration is associated with more risk of PC-AKI compared to IV hydration, but the studies were limited by heterogeneity and lack of hard clinical outcomes [49,50,51]. The CMSC does not recommend the use of oral hydration as the sole preventive strategy for PC-AKI, but unrestricted intake of clear oral fluids in addition to IV volume expansion is supported (Table 2).
Intravenous hydration: saline versus bicarbonate
Normal saline (NaCl 0.9%) and sodium bicarbonate solution (1.4% or 154 mmol NaHCO3 in D5W) are the two most commonly studied crystalloid solutions. The rationale for using bicarbonate is that alkalinisation can reduce the formation of free reactive oxygen species [52]. Initial studies favoured bicarbonate [53,54,55,56], but this was not replicated in later studies [57,58,59,60,61,62], so IV hydration with bicarbonate can be considered equivalent to normal saline.
There is no consensus on the optimal hydration regime. Most studies have compared bicarbonate given pre- and post-CM for less than 6 h [53] to longer duration saline pre- and post-CM protocols (12–24 h). In all studies, there are few patients with eGFR < 30 ml/min/1.73 m2, and evidence about whether short duration bicarbonate is better than long duration saline is conflicting [63,64,65,66,67,68,69,70,71]. There is limited evidence on whether pre-hydration only is inferior to pre- and post-hydration, and only one very short duration bicarbonate protocol has been evaluated [38, 72, 73].
Most studies have been performed in cardiac patients admitted for CA or PCI. Three studies evaluated hydration protocols in patients having contrast-enhanced CT, and did not favour bicarbonate over saline [38, 72, 74]. No studies were identified assessing the beneficial effect of other crystalloids. However, balanced crystalloid solutions, such as Ringer’s lactate, may be preferable in critical care populations, because they avoid the harmful effects of hyperchloraemic acidosis.
The CMSC considers that for IV and IA CM injection with second pass renal exposure either a short bicarbonate hydration regime before CM or a conventional protocol with saline given before and after CM may be used. For IA CM injection with first pass renal exposure conventional protocols with either bicarbonate or saline given before and after CM should be used (Table 2).
Forced diuresis versus conventional hydration
Newer approaches for patients with impaired left ventricular function combine controlled saline hydration with a forced high urinary flow rate to maintain euvolemia and avoid overhydration and several RCTs showed better results than conventional hydration protocols [75,76,77]. Other catheter-based strategies used left ventricular end-diastolic pressure or central venous pressure to guide hydration [78, 79]. In these RCTs the incidence of PC-AKI was lower than with standard IV hydration. Since the forced diuresis studies have heterogeneous populations, interventions and control hydration protocols, their findings cannot be pooled. The CMSC considers that there is not sufficient evidence to recommend forced diuresis.
In which patients should the hydration protocol be individualized?
There is no data to suggest that patients with severe renal impairment (CKD grade V) or severe heart failure (NYHA grade 3–4) should receive different hydration protocols. However, IV hydration with large volumes may exacerbate acute heart failure and induce pulmonary oedema [40]. The opinion of the CMSC is that hydration protocols in these patients should be individualized for type, volume and duration.
Question 8: Which other strategies (pharmaceutical, vitamin, renal replacement therapy) have been proved effective in preventing PC-AKI?
N-Acetylcysteine (NAc)
Most recent RCTs or meta-analyses do not show a protective effect of NAc against PC-AKI following coronary or peripheral angiography [66, 80,81,82,83,84]. NAc also failed to affect clinical outcome in coronary or peripheral angiography [85] or to have a protective effect in CT [86, 87] or in patients with diabetes mellitus undergoing coronary or peripheral angiography [88, 89]. Comparative studies with NAc combined with saline or sodium bicarbonate protocols did not show any additional effect of protective effect of NAc [61, 90,91,92,93]. However, more recent meta-analyses showed a benefit of NAc, with or without high-dose statins, when added to hydration for preventing PC-AKI [94,95,96].
Statins
Several meta-analyses showed lower overall PC-AKI rates with the use of high-dose, short-term statin treatment compared to controls [95,96,97,98,99,100,101,102,103,104,105]. Lower PC-AKI rates were also found in subgroups, such as older patients, patients with acute coronary syndromes and for high-dose statin regimes. Some of these meta-analyses showed a reduced need for RRT after statins, but no reduction in all-cause mortality [97, 102]. However, the US Agency for Healthcare Research and Quality (AHRQ) meta-analysis showed that the risk of PC-AKI was only significantly reduced when statins were added to hydration and NAc. A reduction in PC-AKI risk could not be shown when statins plus hydration were compared to hydration alone in patients not taking statins. The standard of evidence grade was low in both analyses [94].
Despite the many positive results, it is difficult to make a general recommendation for statins [106] because the patients studied were invariably cardiac, and a variety of statin and hydration protocols were used. Patients with CKD grade 3B–5 (eGFR < 45 ml/min/1.73 m2) are under-represented in the studies and results in these patients remain inconclusive [102, 103, 107, 108]. Most patients undergoing CA/PCI are already taking long-term statins, and results in these patients are unclear.
While the CMSC recognises the potential preventive effects of short-term statins, it does not advise the use of short-term, high-dose statins as a single strategy for preventing PC-AKI (Table 2).
RAAS blockade: ACE inhibitors and angiotensin-II receptor blockers
Administration of renin–angiotensin–aldosterone system (RAAS) blockade as a preventive measure for patients not taking these drugs did not show a significant effect on the incidence of PC-AKI in recent meta-analyses [32, 34] (Table 2).
Vitamin C
The majority of RCTs or meta-analyses do not demonstrate a protective effect of vitamin C against PC-AKI in patients with CKD predominantly undergoing coronary angiography [109,110,111] or any benefit of the use of vitamin C, NAc or a combination of both over the standard hydration regimen in preventing PC-AKI [112, 113] (Table 2). Combining vitamin C with pentoxifylline also failed to show an advantage [114]. Only two publications [115, 116] have shown a protective effect of vitamin C in patients with CKD undergoing CA.
Renal replacement therapy (RRT)
There is no convincing evidence in favour of preventive haemodialysis or RRT alone [117,118,119] or combined with hydration [120] in patients with CKD, predominantly undergoing CA (Table 2). There is no evidence of an increased risk of permanent anuria in patients on peritoneal dialysis undergoing CA [121]. There is a single study showing better late-stage (day 5–30) renal protection against PC-AKI with simultaneous haemodialysis [122].
Miscellaneous
The data on the protective effects of several agents, such as trimatizidine [123, 124], theophylline [95, 125,126,127], alprostadil [128, 129], nebivolol [130], fenoldopam [131] and iloprost [132], is not conclusive and does not support recommending their use to reduce the risk of PC-AKI.
Question 9: Should administration of metformin be adapted to reduce the risk of metformin-associated lactic acidosis in patients with type 2 diabetes mellitus scheduled to receive intravascular contrast media?
Metformin is the standard drug for monotherapy of type 2 diabetes mellitus [133]. The effect of CM on the risk of metformin-associated lactic acidosis is indirect, since an episode of AKI following intravascular CM administration may lead to metformin accumulation. The use of metformin in patients with eGFR 30–59 ml/min/1.73 m2 is considered safe if doses are reduced appropriately [134, 135]. Limiting the metformin dose to a maximum of 2000 mg/day for eGFR 45–60 ml/min/1.73 m2 and to a maximum of 1000 mg/day for eGFR 30–44 ml/min/1.73 m2 has been recommended. In patients with eGFR 30–59 ml/min/1.73 m2 metformin drug levels remain within therapeutic ranges. For patients with eGFR < 30 ml/min/1.73 m2 metformin administration is not approved.
Multiple studies and meta-analyses have shown that the risk of lactic acidosis is very low and linked more to the underlying disease and possible co-morbidities rather than the use of metformin [134, 136, 137]. Because of the lack of published evidence on metformin and CM, early guidelines about the need to stop metformin before intravascular CM were based on consensus, and were strict [138, 139]. As the low risk of lactic acidosis became apparent, guidelines have become less restrictive [3].
Since no new published evidence is available, the CMSC has updated its recommendations based on recent recommendations from the FDA [140], and on guidelines from the ACR and RSTN [14, 141] (Table 3).
Question 10: Should the timing of CM administration be adapted to the schedule of haemodialysis or haemofiltration sessions in patients on renal replacement therapy?
Iodine-based CM can be safely removed by haemodialysis (HD) or haemofiltration (HF). Many factors influence the effectiveness of HD, such as flow rate of blood and dialysate, dialysis membrane permeability, HD duration, and CM characteristics such as molecular size, protein binding, hydrophilicity and electrical charge [142].
Although HF concomitant with radiological procedures has been shown to be feasible and well tolerated [143, 144], the fractional removal of iodine-based CM contrast agents is modest and several HF or HD sessions are needed to remove 95% of the administered CM [143]. Also, there is no evidence for the necessity of emergency HD after administration of iodine-based CM in patients on chronic HD [145]. However, to avoid volume overload, CM administration may be synchronised with scheduled HF or HD (Table 3).
Conclusion
Assessment of the risk of PC-AKI before intravascular CM is administered is best done by measuring eGFR but the alternative of a questionnaire for patients detects most patients with eGFR less than 45 ml/min/1.73 m2. Volume expansion with normal saline or sodium bicarbonate remains the mainstay of PC-AKI prevention, but there is still uncertainty about the optimal protocol. The additional benefit of a number of drugs, such as N-acetylcysteine, statins, ACE inhibitors and angiotensin-II receptor blockers, and vitamin C in preventing PC-AKI has not been proved conclusively. Stopping nephrotoxic medications appears to be of limited value in preventing PC-AKI. Recommendations for discontinuing metformin when CM is given have been relaxed and now only apply to patients with eGFR < 30 ml/min/1.73 m2 receiving IV CM or IA CM with second pass renal exposure, and to all patients receiving IA CM with first pass renal exposure or who have AKI. There is no need to adapt dialysis schedules in patients being given intravascular CM.
The recommendations made in this paper have been incorporated into the ESUR CMSC guidelines version 10 (Table 4).
Abbreviations
- ACEI:
-
Angiotensin Converting Enzyme Inhibitor
- ACR:
-
American College of Radiology
- AGREE:
-
Appraisal of Guidelines for Research and Evaluation
- AHRQ:
-
Agency for Healthcare Research and Quality
- AKI:
-
Acute Kidney Injury
- ARB:
-
Angiotensin-II Receptor Blocker
- CA:
-
Coronary Angiography
- CI-AKI:
-
Contrast-Induced Acute Kidney Injury
- CIN:
-
Contrast-Induced Nephropathy
- CKD:
-
Chronic Kidney Disease
- CM:
-
Contrast Media
- CMSC:
-
Contrast Media Safety Committee
- CT:
-
Computed Tomography
- CTPA:
-
Computed Tomography Pulmonary Angiography
- D5W:
-
Dextrose 5% in Water
- eGFR:
-
Estimated Glomerular Filtration Rate
- ESUR:
-
European Society of Urogenital Radiology
- FDA:
-
Federal Drugs Administration
- GFR:
-
Glomerular Filtration Rate
- HD:
-
Haemodialysis
- HF:
-
Haemofiltration
- IA:
-
Intra-Arterial
- IV:
-
Intravenous
- NAc:
-
N-Acetylcysteine
- NaHCO3 :
-
Sodium Bicarbonate
- NSAID:
-
Non-Steroidal Anti-Inflammatory Drug
- NYHA:
-
New York Heart Association
- OCEBM:
-
Oxford Centre for Evidence Based Medicine
- PC-AKI:
-
Post-Contrast Acute Kidney Injury
- PCI:
-
Percutaneous Coronary Intervention
- PICO:
-
Patient–Intervention–Comparator–Outcome
- PS:
-
Propensity Score
- RAAS:
-
Renin–Angiotensin–Aldosterone System
- RSTN:
-
Radiological Society of the Netherlands
- RCT:
-
Randomised Controlled Trial
- RRT:
-
Renal Replacement Therapy
- sCr:
-
Serum Creatinine
- WG:
-
Writing Group
References
Stacul F, van der Molen AJ, Reimer P, Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) et al (2011) Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21:2527–2541
Morcos SK, Thomsen HS, Webb JA, Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR) et al (2002) Dialysis and contrast media. Eur Radiol 12:3026–3030
Contrast Media Safety Committee ESUR. Guidelines on Contrast Media v9. CMSC, 2014. http://www.esur-cm.org/index.php/en/. 15 December 2017
Brouwers M, Kho ME, Browman GP, on behalf of the AGREE Next Steps Consortium et al (2010) AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J 182:E839–E842
Guyatt GH, Oxman AD, Kunz R et al (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395–400
OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653. Accessed 15 December 2017
Choyke PL, Cady J, DePollar SL, Austin H (1998) Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol 4:65–69
Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA (2000) Are screening serum creatinine levels necessary prior to outpatient CT examinations? Radiology 216:481–484
Azzouz M, Romsing J, Thomsen HS (2014) Can a structured questionnaire identify patients with reduced renal function? Eur Radiol 24:780–784
Too CW, Ng WY, Tan CC, Mahmood MI, Tay KH (2015) Screening for impaired renal function in outpatients before iodinated contrast injection: comparing the Choyke questionnaire with a rapid point-of-care-test. Eur J Radiol 84:1227–1231
Zähringer C, Potthast S, Tyndall AJ, Bongartz G, Hohmann J (2015) Serum creatinine measurements: evaluation of a questionnaire according to the ESUR guidelines. Acta Radiol 56:628–634
Chang P, Saddleton E, Laumann AE et al (2012) Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function. Acad Radiol 19:1181–1185
Moos SI, de Weijert RS, Nagan G, Stoker J, Bipat S (2014) Cost of screening for kidney disease before intravenous contrast administration. Neth J Med 72:271–280
Van der Molen AJ, Geenen RWF, Dekkers HM et al for the Radiological Society of the Netherlands (RSTN). Guideline safe use of contrast media, part 1. Vught, RSTN: 2017. https://www.radiologen.nl/secties/nvvr/documenten/richtlijn-veilig-gebruik-van-contrastmiddelen-deel-1-full-english. Accessed 15 December 2017
Tsai TT, Patel UD, Chang TI et al (2014) Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. J Am Heart Assoc 3:e001380
Kooiman J, Gurm HS (2014) Predicting contrast-induced renal complications in the catheterization laboratory. Intervent Cardiol Clin 3:369–377
Mehran R, Aymong ED, Nikolsky E et al (2004) A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44:1393–1399
Sgura FA, Bertelli L, Monopoli D et al (2010) Mehran contrast-induced nephropathy risk score predicts short- and long-term clinical outcomes in patients with ST-elevation-myocardial infarction. Circ Cardiovasc Interv 3:491–498
Tziakas D, Chalikias G, Stakos D et al (2014) Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. Am J Cardiol 113:1487–1493
Abellas-Sequeiros RA, Raposeiras-Roubin S, Abu-Assi E et al (2016) Mehran contrast nephropathy risk score: is it still useful 10 years later? J Cardiol 67:262–267
Sato A, Hoshi T, Kakefuda Y et al (2015) Effect of the Mehran risk score for the prediction of clinical outcomes after percutaneous coronary intervention. J Cardiol 66:417–422
Gurm HS, Seth M, Kooiman J, Share D (2013) A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 61:2242–2248
Silver SA, Shah PS, Chertow GM, Harel S, Wald R, Harel Z (2015) Risk prediction models for contrast induced nephropathy: systematic review. BMJ 351:h4395
Allen DW, Ma B, Leung KC et al (2017) Risk prediction models for contrast-induced acute kidney injury accompanying cardiac catheterization: systematic review and meta-analysis. Can J Cardiol 33(6):724-736
Dutch Federation of Nephrology. Guideline diagnosis and management of chronic kidney disease 2016. https://www.nefro.nl/richtlijnen/diagnostiek-en-behandeling-van-chronische-nierschade-voorlopige-richtlijn-2016-0. Accessed 15 December 2017
Perazella MA (2005) Drug-induced nephropathy: an update. Expert Opin Drug Saf 4:689–704
Diogo LP, Saitovitch D, Biehl M et al (2010) Is there an association between non-steroidal anti-inflammatory drugs and contrast nephropathy? Arq Bras Cardiol 95:726–731
Ho YF, Hsieh KL, Kung FL, et al (2015) Nephrotoxic polypharmacy and risk of contrast medium-induced nephropathy in hospitalized patients undergoing contrast-enhanced CT. AJR Am J Roentgenol 205:703–708
Moos SI, van Vemde DN, Stoker J, Bipat S (2013) Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol 82:e387–e399
Rosenstock JL, Bruno R, Kim JK et al (2008) The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 40:749–755
Bainey KR, Rahim S, Etherington K, CAPTAIN Investigators et al (2015) Effects of withdrawing vs. continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: results from the angiotensin converting enzyme inhibitor/angiotensin receptor blocker and contrast induced nephropathy in patients receiving cardiac catheterization (CAPTAIN) trial. Am Heart J 170:110–116
Jo SH, Lee JM, Park J, Kim HS (2015) The impact of renin-angiotensin-aldosterone system blockade on contrast-induced nephropathy: a meta-analysis of 12 studies with 4,493 patients. Cardiology 130:4–14
Peng F, Su J, Lin J, Niu W (2015) Impact of renin-angiotensin-aldosterone system-blocking agents on the risk of contrast-induced acute kidney injury: a prospective study and meta-analysis. J Cardiovasc Pharmacol 65:262–268
Wu Z, Zhang H, Jin W et al (2015) The effect of renin-angiotensin-aldosterone system blockade medications on contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis. PLoS One 10:e0129747
Chen SL, Zhang J, Yei F et al (2008) Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. Int J Cardiol 126:407–413
Luo Y, Wang X, Ye Z, et al (2014) Remedial hydration reduces the incidence of contrast-induced nephropathy and short-term adverse events in patients with ST-segment elevation myocardial infarction: a single-center, randomized trial. Intern Med 53:2265–2272
Jurado-Roman A, Hernandez-Hernandez F, Garcia-Tejada J et al (2015) Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Am J Cardiol 115:1174–1178
Kooiman J, Sijpkens YW, van Buren M et al (2014) Randomised trial of no hydration vs. sodium bicarbonate hydration in patients with chronic kidney disease undergoing acute computed tomography-pulmonary angiography. J Thromb Haemost 12:1658–1666
Trivedi HS, Moore H, Nasr S et al (2003) A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 93:C29–C34
Nijssen EC, Rennenberg RJ, Nelemans PJ et al (2017) Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 389:1312–1322
Taylor AJ, Hotchkiss D, Morse RW, McCabe J (1998) PREPARED: preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 114:1570–1574
Dussol B, Morange S, Loundoun A, Auquier P, Berland Y (2006) A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 21:2120–2126
Lawlor DK, Moist L, DeRose G et al (2007) Prevention of contrast-induced nephropathy in vascular surgery patients. Ann Vasc Surg 21:593–597
Wrobel W, Sinkiewicz W, Gordon M, Wozniak-Wisniewska A (2010) Oral versus intravenous hydration and renal function in diabetic patients undergoing percutaneous coronary interventions. Kardiol Pol 68:1015–1020
Akyuz S, Karaca M, Kemaloglu OT et al (2014) Efficacy of oral hydration in the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography or intervention. Nephron Clin Pract 128:95–100
Cho R, Javed N, Traub D, Kodali S, Atem F, Srinivasan V (2010) Oral hydration and alkalinization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease. J Interv Cardiol 23:460–466
Kong DG, Hou YF, Ma LL, Yao DK, Wang LX (2012) Comparison of oral and intravenous hydration strategies for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography or angioplasty: a randomized clinical trial. Acta Cardiol 67:565–569
Martin-Moreno PL, Varo N, Martinez-Anso E et al (2015) Comparison of intravenous and oral hydration in the prevention of contrast-induced acute kidney injury in low-risk patients: a randomized trial. Nephron 131:51–58
Hiremath S, Akbari A, Shabana W, Fergusson DA, Knoll GA (2013) Prevention of contrast-induced acute kidney injury: is simple oral hydration similar to intravenous? A systematic review of the evidence. PLoS One 8:e60009
Cheungpasitporn W, Thongprayoon C, Brabec BA, Edmonds PJ, O'Corragain OA, Erickson SB (2014) Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures: a systematic review and meta-analysis of randomized controlled trials. N Am J Med Sci 6:618–624
Agarwal SK, Mohareb S, Patel A et al (2015) Systematic oral hydration with water is similar to parenteral hydration for prevention of contrast-induced nephropathy: an updated meta-analysis of randomised clinical data. Open Heart 2:e000317
Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C (2010) Reactive oxygen species and the pathogenesis of radiocontrast-induced nephorpathy. Invest Radiol 45:188–193
Merten GJ, Burgess WP, Gray LV et al (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291:2328–2334
Masuda M, Yamada T, Mine T et al (2007) Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 100:781–786
Ozcan EE, Guneri S, Akdeniz B et al (2007) Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 154:539–544
Recio-Mayoral A, Chaparro M, Prado B et al (2007) The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 49:1283–1288
Adolph E, Holdt-Lehmann B, Chatterjee T et al (2008) Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 19:413–419
Brar SS, Shen AY, Jorgensen MB et al (2008) Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 300:1038–1046
Boucek P, Havrdova T, Oliyarnyk O et al (2013) Prevention of contrast-induced nephropathy in diabetic patients with impaired renal function: a randomized, double blind trial of sodium bicarbonate versus sodium chloride-based hydration. Diabetes Res Clin Pract 101:303–308
Gomes VO, Lasevitch R, Lima VC et al (2012) Hydration with sodium bicarbonate does not prevent contrast nephropathy: a multicenter clinical trial. Arq Bras Cardiol 99:1129–1134
Ratcliffe JA, Thiagarajah P, Chen J et al (2009) Prevention of contrast-induced nephropathy: a randomized controlled trial of sodium bicarbonate and N-acetylcysteine. Int J Angiol 18:193–197
Solomon R, Gordon P, Manoukian SV et al (2015) Randomized trial of bicarbonate or saline study for the prevention of contrast-induced nephropathy in patients with CKD. Clin J Am Soc Nephrol 10:1519–1524
Briguori C, Airoldi F, D'Andrea D et al (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115:1211–1217
Castini D, Lucreziotti S, Bosotti L et al (2010) Prevention of contrast-induced nephropathy: a single center randomized study. Clin Cardiol 33:E63–E68
Chong E, Poh KK, Lu Q et al (2015) Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): a multi-centre, randomised, controlled trial. Int J Cardiol 201:237–242
Hafiz AM, Jan MF, Mori N et al (2012) Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies. Catheter Cardiovasc Interv 79:929–937
Koc F, Ozdemir K, Altunkas F et al (2013) Sodium bicarbonate versus isotonic saline for the prevention of contrast-induced nephropathy in patients with diabetes mellitus undergoing coronary angiography and/or intervention: a multicenter prospective randomized study. J Investig Med 61:872–877
Klima T, Christ A, Marana I et al (2012) Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. Eur Heart J 33:2071–2079
Lee SW, Kim WJ, Kim YH et al (2011) Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol 107:1447–1452
Maioli M, Toso A, Leoncini M et al (2008) Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 52:599–604
Shavit L, Korenfeld R, Lifschitz M, Butnaru A, Slotki I (2009) Sodium bicarbonate versus sodium chloride and oral N-acetylcysteine for the prevention of contrast-induced nephropathy in advanced chronic kidney disease. J Interv Cardiol 22:556–563
Kooiman J, Sijpkens YW, de Vries JP et al (2014) A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography. Nephrol Dial Transplant 29:1029–1036
Kooiman J, de Vries JP, van der Heyden J et al (2014) Randomized trial of 1-hour sodium bicarbonate vs. Standard saline hydration in patients with chronic kidney disease undergoing intra-arterial contrast administration [abstr]. Circulation 130:A17645
Kama A, Yilmaz S, Yaka E et al (2014) Comparison of short-term infusion regimens of N-acetylcysteine plus intravenous fluids, sodium bicarbonate plus intravenous fluids, and intravenous fluids alone for prevention of contrast-induced nephropathy in the emergency department. Acad Emerg Med 21:615–622
Briguori C, Visconti G, Focaccio A et al (2011) Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation 124:1260–1269
Marenzi G, Ferrari C, Marana I et al (2012) Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv 5:90–97
Usmiani T, Andreis A, Budano C et al (2016) AKIGUARD (Acute Kidney Injury GUARding Device) trial: in-hospital and one-year outcomes. J Cardiovasc Med 17:530–537
Brar SS, Aharonian V, Mansukhani P et al (2014) Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. Lancet 383:1814–1823
Qian G, Fu Z, Guo J, Cao F, Chen Y (2016) Prevention of contrast-induced nephropathy by central venous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients. JACC Cardiovasc Interv 9:89–96
Aslanger E, Uslu B, Akdeniz C, Polat N, Cizgici Y, Oflaz H (2012) Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis 23:265–270
Inda-Filho AJ, Caixeta A, Manggini M, Schor N (2014) Do intravenous N-acetylcysteine and sodium bicarbonate prevent high osmolal contrast-induced acute kidney injury? A randomized controlled trial. PLoS One 9:e107602
Jaffery Z, Verma A, White CJ et al (2012) A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv 79:921–926
O'Sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR (2013) The role of N-acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology 64:576–582
Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z (2013) Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One 8:e55124
Loomba RS, Shah PH, Aggarwal S, Arora RR (2016) Role of N-acetylcysteine to prevent contrast-induced nephropathy: a meta-analysis. Am J Ther 23:e172–e183
Traub SJ, Mitchell AM, Jones AE et al (2013) N-acetylcysteine plus intravenous fluids versus intravenous fluids alone to prevent contrast-induced nephropathy in emergency computed tomography. Ann Emerg Med 62:511–520
Poletti PA, Platon A, De Seigneux S et al (2013) N-acetylcysteine does not prevent contrast nephropathy in patients with renal impairment undergoing emergency CT: a randomized study. BMC Nephrol 14:119
Berwanger O, Cavalcanti AB, Sousa AM et al (2013) Acetylcysteine for the prevention of renal outcomes in patients with diabetes mellitus undergoing coronary and peripheral vascular angiography: a substudy of the acetylcysteine for contrast-induced nephropathy trial. Circ Cardiovasc Interv 6:139–145
Kang X, Hu DY, Li CB, Ai ZS, Peng A (2015) N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. Ren Fail 37:297–303
Brown JR, Block CA, Malenka DJ, O'Connor GT, Schoolwerth AC, Thompson CA (2009) Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv 2:1116–1124
Carbonell N, Blasco M, Sanjuan R et al (2007) Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol 115:57–62
Heng AE, Cellarier E, Aublet-Cuvelier B et al (2008) Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date? Clin Nephrol 70:475–484
Staniloae CS, Doucet S, Sharma SK et al (2009) N-Acetylcysteine added to volume expansion with sodium bicarbonate does not further prevent contrast-induced nephropathy: results from the cardiac angiography in renally impaired patients study. J Interv Cardiol 22:261–265
Subramaniam RM, Suarez-Cuervo C, Wilson RF et al (2016) Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med 164:406–416
Ali-Hassan-Sayegh S, Mirhosseini SJ, Ghodratipour Z et al (2017) Strategies preventing contrast-induced nephropathy after coronary angiography: a comprehensive meta-analysis and systematic review of 125 randomized controlled trials. Angiology 68:389–413
Su X, Xie X, Liu L et al (2017) Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: A systematic review and Bayesian network analysis. Am J Kidney Dis 69:69–77
Briasoulis A, Mallikethi-Reddy S, Sharma S, Briasouli AA, Afonso L (2015) 3-Hydroxy-3-methylglutaryl-CoA reductase enzyme inhibitors for prevention of contrast-induced nephropathy: a meta-analysis of prospective randomized controlled studies. Am J Ther 22:e158–e166
Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al (2015) Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials. Ren Fail 37:664–671
Li H, Wang C, Liu C, Li R, Zou M, Cheng G (2016) Efficacy of short-term statin treatment for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a meta-analysis of 21 randomized controlled trials. Am J Cardiovasc Drugs 16:201–219
Liu YH, Liu Y, Duan CY et al (2015) Statins for the prevention of contrast-induced nephropathy after coronary angiography/percutaneous interventions: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 20:181–192
Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL (2015) A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol 183:47–53
Thompson K, Razi R, Lee MS et al (2016) Statin use prior to angiography for the prevention of contrast-induced acute kidney injury: a meta-analysis of 19 randomised trials. EuroIntervention 12:366–374
Wang N, Qian P, Yan TD, Phan K (2016) Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: A systematic review and trial sequential analysis. Int J Cardiol 206:143–152
Wu H, Li D, Fang M, Han H, Wang H (2015) Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention. J Clin Pharmacol 55:123–131
Yang Y, Wu YX, Hu YZ (2015) Rosuvastatin treatment for preventing contrast-induced acute kidney injury after cardiac catheterization: a meta-analysis of randomized controlled trials. Medicine 94:e1226
Vanmassenhove J, Vanholder R, Lameire N (2016) Statins for the prevention of contrast-induced acute kidney injury. Curr Opin Nephrol Hypertens 25:508–517
Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C (2014) Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. Am J Cardiol 114:541–548
Han Y, Zhu G, Han L et al (2014) Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 63:62–70
Brueck M, Cengiz H, Hoeltgen R et al (2013) Usefulness of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced acute kidney injury in patients undergoing elective cardiac catheterization: a single-center, prospective, randomized, double-blind, placebo-controlled trial. J Invasive Cardiol 25:276–283
Dvorsak B, Kanic V, Ekart R, Bevc S, Hojs R (2013) Ascorbic acid for the prevention of contrast-induced nephropathy after coronary angiography in patients with chronic renal impairment: a randomized controlled trial. Ther Apher Dial 17:384–390
Li R, Chen H (2012) Prevention of contrast-induced nephropathy with ascorbic acid. Heart 98:E211
Albabtain MA, Almasood A, Alshurafah H, Alamri H, Tamim H (2013) Efficacy of ascorbic acid, N-acetylcysteine, or combination of both on top of saline hydration versus saline hydration alone on prevention of contrast-Induced nephropathy: a prospective randomized study. J Interv Cardiol 26:90–96
Zhou L, Chen H (2012) Prevention of contrast-induced nephropathy with ascorbic acid. Intern Med 51:531–535
Shakeryan F, Sanati H, Fathi H et al (2013) Evaluation of combination therapy with vitamin C and pentoxifylline on preventing kidney failure secondary to intravenous contrast material in coronary angioplasty. Iran Heart J 14:17–21
Sadat U, Usman A, Gillard JH, Boyle JR (2013) Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials. J Am Coll Cardiol 62:2167–2175
Wang XT, Yan J, Li L, Su Q (2014) Anti-oxidative vitamin for the prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: meta-analysis of randomized controlled trials. Exp Clin Cardiol 20:1385–1410
Cruz DN, Perazella MA, Bellomo R et al (2006) Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 48:361–371
Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA (2012) Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med 125:66–78
Song K, Jiang S, Shi Y, Shen H, Shi X, Jing D (2010) Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Nephrol 32:497–504
Reinecke H, Fobker M, Wellmann J et al (2007) A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) trial. Clin Res Cardiol 96:130–139
Weisbord SD, Bernardini J, Mor MK et al (2006) The effect of coronary angiography on residual renal function in patients on peritoneal dialysis. Clin Cardiol 29:494–497
Choi MJ, Yoon JW, Han SJ et al (2014) The prevention of contrast-induced nephropathy by simultaneous hemofiltration during coronary angiographic procedures: a comparison with periprocedural hemofiltration. Int J Cardiol 176:941–945
Nadkarni GN, Konstantinidis I, Patel A et al (2015) Trimetazidine decreases risk of contrast-induced nephropathy in patients with chronic kidney disease: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 20:539–546
Ye Z, Lu H, Su Q et al (2017) Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: an updated systematic review and meta-analysis. Medicine 96:e6059
Bilasy ME, Oraby MA, Ismail HM, Maklady FA (2012) Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures. J Interv Cardiol 25:404–410
Dai B, Liu Y, Fu L, Li Y, Zhang J, Mei C (2012) Effect of theophylline on prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 60:360–370
Matejka J, Varvarovsky I, Vojtisek P et al (2010) Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. Heart Vessels 25:536–542
Miao Y, Zhong Y, Yan H, Li W, Wang BY, Jin J (2013) Alprostadil plays a protective role in contrast-induced nephropathy in the elderly. Int Urol Nephrol 45:1179–1185
Ye Z, Lu H, Guo W et al (2016) The effect of alprostadil on preventing contrast induced nephropathy for percutaneous coronary intervention in diabetic patients: a systematic review and meta-analysis. Medicine 95:e5306
Thamcharoen N, Thongprayoon C, Edmonds PJ, Cheungpasitporn W (2015) Periprocedural nebivolol for the prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. N Am J Med Sci 7:446–451
Naeem M, McEnteggart GE, Murphy TP, Prince E, Ahn S, Soares G (2015) Fenoldopam for the prevention of contrast-induced nephropathy (CIN) - do we need more trials? A meta-analysis. Clin Imaging 39:759–764
Kassis HM, Minsinger KD, McCullough PA, Block CA, Sidhu MS, Brown JR (2015) A review of the use of Iloprost, a synthetic prostacyclin, in the prevention of radiocontrast nephropathy in patients undergoing coronary angiography and intervention. Clin Cardiol 38:492–498
Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668–2675
Lu WR, Defilippi J, Braun A (2013) Unleash metformin: reconsideration of the contraindication in patients with renal impairment. Ann Pharmacother 47:1488–1497
Richy FF, Sabido-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U (2014) Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care 37:2291–2295
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 14:CD002967
Goergen SK, Rumbold G, Compton G, Harris C (2010) Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin. Radiology 254:261–269
Thomsen HS, Morcos SK, ESUR CMSC (1999) Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media. Eur Radiol 9:738-740
Food and Drug Administration (FDA) (2016) FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed 15 December 2017
ACR Committee on Drugs and Contrast Media (2017) ACR manual on contrast media, v10.3. American College of Radiology. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed 15 December 2017
Morcos SK, Thomsen HS, Webb JA (2002) Dialysis and contrast media. Eur Radiol 12:3026–3030
Gabutti L (2003) Does continuous venovenous hemodiafiltration concomitant with radiological procedures provide a significant and safe removal of the iodinated contrast ioversol? Blood Purif 21:152–157
Shinoda T, Hata T, Nakajima K, Yoshimoto H, Niwa A (2002) Time-course of iodine elimination by hemodialysis in patients with renal failure after angiography. Ther Apher 6:437–442
Younathan CM, Kaude JV, Cook MD, Shaw GS, Peterson JC (1994) Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. AJR Am J Roentgenol 163:969–971
Funding
The authors state that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Prof. Henrik S. Thomsen.
Conflict of interest
Aart van der Molen has received incidental payments for lectures and chairmanships at scientific meetings for contrast agent safety related issues (contrast agent reactions, Gd-retention) from GE, Bayer, Bracco and Guerbet.
Fulvio Stacul has received lecture fees from Bracco and Guerbet.
Olivier Clément has received lecture fees from Bracco and Guerbet.
The other authors of this manuscript declare no relationships with any companies whose products and services may be related to the subject matter of this article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was not required for this study because this is a special paper based on other publications. Thus informed consent is not necessary.
Ethical approval
Institutional review board approval was not required because it is a retrospective study based on other studies.
Methodology
• retrospective
• multicentre study
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
van der Molen, A.J., Reimer, P., Dekkers, I.A. et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients. Eur Radiol 28, 2856–2869 (2018). https://doi.org/10.1007/s00330-017-5247-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-017-5247-4